708 related articles for article (PubMed ID: 15338781)
21. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
22. [New approaches for allergen-specific immunotherapy].
Cantillo JF; Puerta L
Biomedica; 2010; 30(3):440-53. PubMed ID: 21713346
[TBL] [Abstract][Full Text] [Related]
23. The safety of allergen immunotherapy: a literature review.
Cook PR; Farias C
Ear Nose Throat J; 1998 May; 77(5):378-9, 383-8. PubMed ID: 9615518
[TBL] [Abstract][Full Text] [Related]
24. Immunological mechanisms of allergen-specific immunotherapy.
Larché M; Akdis CA; Valenta R
Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509
[TBL] [Abstract][Full Text] [Related]
25. Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials.
Senti G; Freiburghaus AU; Kundig TM
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):582-6. PubMed ID: 20827178
[TBL] [Abstract][Full Text] [Related]
26. Allergen immunotherapy with heat-killed Listeria monocytogenes alleviates peanut and food-induced anaphylaxis in dogs.
Frick OL; Teuber SS; Buchanan BB; Morigasaki S; Umetsu DT
Allergy; 2005 Feb; 60(2):243-50. PubMed ID: 15647048
[TBL] [Abstract][Full Text] [Related]
27. [Practice of hyposensitization in allergic diseases].
Wüthrich B
Schweiz Rundsch Med Prax; 1993 May; 82(18):534-9. PubMed ID: 8497763
[TBL] [Abstract][Full Text] [Related]
28. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
[TBL] [Abstract][Full Text] [Related]
29. How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma?
Jacobsen L; Valovirta E
Curr Opin Allergy Clin Immunol; 2007 Dec; 7(6):556-60. PubMed ID: 17989534
[TBL] [Abstract][Full Text] [Related]
30. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
Moingeon P; Mascarell L
Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
[TBL] [Abstract][Full Text] [Related]
31. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production.
Cosmi L; Santarlasci V; Angeli R; Liotta F; Maggi L; Frosali F; Rossi O; Falagiani P; Riva G; Romagnani S; Annunziato F; Maggi E
Clin Exp Allergy; 2006 Mar; 36(3):261-72. PubMed ID: 16499636
[TBL] [Abstract][Full Text] [Related]
32. Allergen immunotherapy: definition, indications, and reactions.
Lei DK; Saltoun C
Allergy Asthma Proc; 2019 Nov; 40(6):369-371. PubMed ID: 31690372
[TBL] [Abstract][Full Text] [Related]
33. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].
Malling HJ
Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284
[TBL] [Abstract][Full Text] [Related]
34. [Non-specific immunotherapy for the treatment of allergic diseases].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2000 May; 8(47):309-15. PubMed ID: 10944949
[TBL] [Abstract][Full Text] [Related]
35. Pro and contra of specific hyposensitization.
Karl S; Ring J
Eur J Dermatol; 1999 Jun; 9(4):325-31. PubMed ID: 10356415
[TBL] [Abstract][Full Text] [Related]
36. An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.
Ozdemir C
Ther Adv Respir Dis; 2009 Oct; 3(5):253-62. PubMed ID: 19880430
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life.
Zeldin Y; Weiler Z; Magen E; Tiosano L; Kidon MI
Isr Med Assoc J; 2008 Dec; 10(12):869-72. PubMed ID: 19160945
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
39. [The value of immunotherapy in treatment of IgE-induced allergic diseases].
Müller UR
Ther Umsch; 1994 Jan; 51(1):67-76. PubMed ID: 7511841
[TBL] [Abstract][Full Text] [Related]
40. High-affinity IgG to a major A. fumigatus allergen, Asp f 2, retards allergic response.
Svirshchevskaya EV; Viskova N; Shevchenko M; Alekseeva L; Marchenko A; Benevolensky S; Kurup VP
Med Sci Monit; 2004 Oct; 10(10):BR371-80. PubMed ID: 15448590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
